Exelixis Inc. [EXEL] Is Currently -0.20 below its 200 Period Moving Avg: What Does This Mean?


Exelixis Inc. [NASDAQ: EXEL] price plunged by -0.20 percent to reach at -$0.04. The company report on May 10, 2022 that Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


– Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million -.

– GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.26 -.

A sum of 3668792 shares traded at recent session while its average daily volume was at 2.21M shares. Exelixis Inc. shares reached a high of $20.01 and dropped to a low of $19.39 until finishing in the latest session at $19.80.

The one-year EXEL stock forecast points to a potential upside of 27.13. The average equity rating for EXEL stock is currently 1.90, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Exelixis Inc. [EXEL]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXEL shares is $27.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXEL stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Exelixis Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 19, 2021. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on November 03, 2021, representing the official price target for Exelixis Inc. stock. Previously, the target price had yet another raise to $28, while Jefferies analysts kept a Buy rating on EXEL stock. On August 06, 2021, analysts increased their price target for EXEL shares from 35 to 64.

The Average True Range (ATR) for Exelixis Inc. is set at 0.82, with the Price to Sales ratio for EXEL stock in the period of the last 12 months amounting to 4.58. The Price to Book ratio for the last quarter was 2.84, with the Price to Cash per share for the same quarter was set at 4.42. Price to Free Cash Flow for EXEL in the course of the last twelve months was 19.54 with Quick ratio for the last quarter at 5.40.

EXEL Stock Performance Analysis:

Exelixis Inc. [EXEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.17. With this latest performance, EXEL shares dropped by -11.49% in over the last four-week period, additionally plugging by 7.96% over the last 6 months – not to mention a drop of -22.20% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXEL stock in for the last two-week period is set at 32.64, with the RSI for the last a single of trading hit 27.34, and the three-weeks RSI is set at 37.64 for Exelixis Inc. [EXEL]. The present Moving Average for the last 50 days of trading for this stock 21.84, while it was recorded at 20.05 for the last single week of trading, and 19.70 for the last 200 days.

Insight into Exelixis Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Exelixis Inc. [EXEL] shares currently have an operating margin of +19.98 and a Gross Margin at +96.32. Exelixis Inc.’s Net Margin is presently recorded at +16.10.

Return on Equity for this stock inclined to 11.30, with Return on Assets sitting at 9.70.

Exelixis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.40.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EXEL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Exelixis Inc. go to 46.00%.

Exelixis Inc. [EXEL] Insider Position Details

There are presently around $5,443 million, or 85.20% of EXEL stock, in the hands of institutional investors. The top three institutional holders of EXEL stocks are: BLACKROCK INC. with ownership of 32,884,561, which is approximately 1.881% of the company’s market cap and around 1.20% of the total institutional ownership; VANGUARD GROUP INC, holding 30,059,689 shares of the stock with an approximate value of $596.38 million in EXEL stocks shares; and FMR LLC, currently with $373.09 million in EXEL stock with ownership of nearly -0.045% of the company’s market capitalization.

Positions in Exelixis Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 180 institutional holders increased their position in Exelixis Inc. [NASDAQ:EXEL] by around 17,467,492 shares. Additionally, 156 investors decreased positions by around 13,978,675 shares, while 57 investors held positions by with 242,908,398 shares. The mentioned changes placed institutional holdings at 274,354,565 shares, according to the latest SEC report filing. EXEL stock had 55 new institutional investments in for a total of 2,185,086 shares, while 40 institutional investors sold positions of 1,760,486 shares during the same period.